ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-OR003

Clinical Effects of Molecular Hydrogen (H2) Delivery during Hemodialysis in Chronic Dialysis Patients: Five Years Prospective Observational Study

Session Information

Category: Dialysis

  • 606 Dialysis: Epidemiology, Outcomes, Clinical Trials - Cardiovascular

Authors

  • Nakayama, Masaaki, Tohoku University, Tohoku University Hospital, Sendai City, Japan
  • Zhu, Wan-Jun, Tohoku University, Tohoku University Hospital, Sendai City, Japan
  • Yamamoto, Tae, Tohoku University, Sendai, MIYAGI, Japan
  • Miyazaki, Mariko, Tohoku University Hospital, Sendai, Japan
  • Ito, Sadayoshi, Tohoku Graduate School of Medicine, Sendai Miyagi, Japan
Background

Enhanced oxidative stress and inflammation are supposed to play a crucial role for poor clinical outcomes in patients on chronic hemodialysis (HD) treatment. Recent studies have revealed unique biological characteristics of molecular hydrogen (H2) as an anti-inflammatory agent. Thus, we developed a novel hemodialysis (E-HD) system which delivers H2 (30 to 80 ppb)-enriched dialysis solution by water electrolysis technique, and conducted a prospective study (UMIN000004857) to study the clinical impact of E-HD as compared to the conventional-HD (C-HD).

Methods

Prevalent chronic HD patients (n=309, mean HD vintage, 7.8 years; age, 66 years old; male, 57%; history of cardio- and cerebro-vascular disease (CVD), 29%)were registered from 7 HD centers in Japan (from Mar 2011 to Dec 2012), and allocated to either E-HD (n= 161), orC-HD (n=148). They had been treated by the respective HD treatments during the study. Primary end-point was composite of all-cause of mortality, and development of non-lethal CVDs (apoplexy, cardiac diseases, and peripheral artery disease).

Results

During the five-year observation periods (end of Oct 2016), no differences were found in dialysis parameters between the two groups. However, there were uniquechanges in clinical profiles in patients on E-HD, i.e. significant reduction in post-HD systolic BP in those who had remained hypertensive state after HD at baseline, which was accompanied by significant reductions ofprescriptions of anti-hypertensive agents. There were 91 events during the mean observation periods of 3.28 years. The number of primary events were 50 cases in C-HD (17 in death and 29 in CVD: Event Rate; 107.1 /1000 patients-year:95%CI:81.2-141.1), and 41 cases in E-HD (20 in death and 20 in CVD:Event Rate;75.4:55.6-102.2), respectively.Multivariate analysis of Cox proportional hazard model revealed that E-HD was an independent significant factor for the primary event (HR 0.59, 95%CI:0.38-0.92) after adjusting for confounding factors (age, history of CVD, serum albumin, and CRP).

Conclusion

The data indicates E-HD could improve prognosis of chronic HD patients, through the unique BP control effect during HD treatment.

Funding

  • Commercial Support